玻璃體腔內(nèi)注射貝伐單抗(Bevacizumab)聯(lián)合眼底激光治療視網(wǎng)膜分支靜脈阻塞繼發(fā)黃斑水腫的療效研究.pdf

1、上海交通大學(xué)碩士學(xué)位論文玻璃體腔內(nèi)注射貝伐單抗（Bevacizumab）聯(lián)合眼底激光治療視網(wǎng)膜分支靜脈阻塞繼發(fā)黃斑水腫的療效研究姓名：王雯秋申請學(xué)位級別：碩士專業(yè)：眼科學(xué)指導(dǎo)教師：孫曉東20090513IntravitrealBevacizumab(Avastin)CombinedwithLaserPhotocoagulationfTreatmentofMacularEdemaSecondarytoBranchRetinalVeinOc

2、clusionAbstractObjectiveToobservetheefficacyofintravitrealbevacizumab(Avastin)combinedwithAgronlaserftreatmentofmacularedemasecondarytoretinalveinocclusion(BRVO).MethodsRetrospectivereviewof12eyesof12patientswhounderwent

3、BRVOweretreatedwithatleastoneintravitrealinjection(1.25mg)ofBevacizumabcombinedwithlaserphotocoagulation.Bestcrectedvisualacuity(BCVA)fundusphotographyopticalcoherencetomography（OCT）fluesceinangiography(FFA)microperimetr

4、y(MP1)werecommitted.Patientswerefollowedf12months.ResultsTherewere12consecutivepatientswhoreceivedintravitrealbevacizumabinjectionsofameannumberofretreatmentswas3.081.08.Eleven(91.67%)ofthe12eyesshowedimprovedBCVAone(8.3

5、％)maintainedafter12monthfollowup.ThemeanCFTdecreasedfrom533.25109.26matbaselineto365.42120.95mat1month283.00128.25mat3months230.0057.37mat6months219.5656.58matlastfollowup(P0.05).2(16.67%)ofthe12eyescontinuedtoshowsustai

6、nedmacularedemabythelastfollowupthesideeffectswerenotobserved.ConclusionsIntravitrealBevacizumabinjectionsresultedBCVAanatomicimprovementsineyeswithmacularedemaattributabletoBRVO.ThereboundMEmainlycausedbyvularleakagecou

7、ldbedetectedinFFA.MultipleinjectionsareneededfcontinuedcontrolpreservationofBCVAinthelongterm.Combinedwithlaserphotocoagulationcouldreducetherateofrecurrenceofmacularedema.KeywdsBranchretinalveinocclusionMacularedemaAnti